• Development of a recombinant fusion protein vaccine formulation to protect against Streptococcus pyogenes. G Morefield, G Touhey, F Lu, A Dunham, and H HogenEsch. Vaccine 32:3810-3815, 2014.

  • A Rational, Systematic Approach for the Development of Vaccine Formulations. Morefield GL. The AAPS Journal. 13(2): 191-200, 2011.
  • An alternative approach to combination vaccines: intradermal administration of isolated components for control of anthrax, botulism, plague and staphylococcal toxic shock. Morefield GL, Tammariello RF, Purcell BK, Worsham PL, Chapman J, Smith LA, Alarcon JB, Mikszta JA, Ulrich RG. J Immune Based Ther Vaccines. 6:5, 2008.
  • Toll-like receptor 4 agonist enhances vaccine efficacy in an experimental model of toxic shock syndrome. Morefield GL, Hawkins LD, Ishizaka ST, Kissner TL, Ulrich RG. Synthetic. Clin Vaccine Immunol. 11:1499-504, 2007.
  • Relationship of adsorption mechanism of antigens by aluminum-containing adjuvants to in vitro elution in interstitial fluid. Jiang D, Morefield GL, HogenEsch H, Hem S. Vaccine. 24:1665-9, 2006.
  • Effect of phosphorylation of ovalbumin on adsorption by aluminum-containing adjuvants and elution upon exposure to interstitial fluid. Morefield GL, Jiang D, HogenEsch H, Hem S. Vaccine. 23:1502-6, 2005.
  • Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Morefield GL, Sokolovska A, Jiang D, HogenEsch H, Robinson JP, Hem SL. Vaccine. 23:1588-95, 2005.
  • Distribution of adsorbed antigen in mono-valent and combination vaccines. Morefield GL, HogenEsch H, Robinson JP, Hem S. Vaccine. 22:1973-84, 2004.
  • Affect of Thermal Treatment During the Preparation of Aluminum Hydroxide Adjuvant on the Protein Adsorption Capacity During Aging. Dandashli E, Zhao Q, Yitta S, Morefield GL, White J, Hem S. Pharmaceutical Development and Technology. 7:401-6, 2002.